Novo Nordisk: Q4 Earnings Exceed Expectations (NVO)

[Para 1: The Lead] Novo Nordisk A/S (NVO) reported a 4th quarter net income of $4.19 billion, surpassing Wall Street expectations. The company's earnings per share were 94 cents, adjusted for non-recurring costs, marking a 10% increase over the previous quarter. Revenue for the quarter was $12.34 billion, exceeding forecasts by 2%. [Para 2-3: Supporting details & Context] For the fiscal year, Novo Nordisk reported a profit of $15.51 billion, or $3.49 per share, a 12% increase from the prior year. The company's drug sales, particularly in diabetes and obesity treatments, continued to drive growth. Analysts had forecasted earnings of $3.41 per share on revenue of $46.3 billion. Novo Nordisk's strong performance is attributed to robust sales and effective cost management strategies.